[1] LIM S,LI W,KEMPER J,et al. Biomarkers and the prediction of adverse outcomes in preeclampsia: a systematic review and meta-analysis[J]. Obstet Gynecol,2021,137(1): 72-81.
[2] GUBENSEK J,PONIKVAR R,PREMRU SRSEN T,et al. Treatment of preeclampsia at extremely preterm gestation with therapeutic plasma exchange[J]. Clin Nephrol,2021,96(1): 101-106.
[3] SHAMS N,KHOSHTINAT NIKKHOI S,GU Z,et al. Isolation and characterization of human anti-CD20 single-chain variable fragment (scFv) from a Naive human scFv library[J]. Med Oncol,2022,
39(11): 177.
[4] 陈佳,郭静,韩悦,等. 联合检测妊娠早中期孕妇血清PAPP-A、PLGF及子宫动脉血流参数预测子痫前期的临床意义[J]. 解放军医药杂志,2021,33(2): 60-64.
[5] GORRIS H H,BADE S,ROCKENDORF N,et al. Pushing antibody-based labeling systems to higher sensitivity by linker-assisted affinity enhancement[J]. Bioconjug Chem,2011,22(8):1619-1624.
[6] BEMANI P,MOHAMMADI M,HAKAKIAN A. ScFv improvement approaches[J]. Protein Pept Lett,2018,25(3):222-229.
[7] LIU C,KOBASHIGAWA Y,YAMAUCHI S,et al. Preparation of single-chain Fv antibodies in the cytoplasm of Escherichia coli by simplified and systematic chaperone optimization[J]. J Biochem,2019,166(6):455-462.
[8] NAVABI P,GANJALIKHANY M R,JAFARI S,et al. Designing and generating a single-chain fragment variable(scFv) antibody against IL2Ralpha(CD25):an in silico and in vitro study[J]. Iran J Basic Med Sci,2021,24(3):360-368.
[9] ARSLAN M,KARADAG M,ONAL E,et al. Effect of non-repetitive linker on in vitro and in vivo properties of an anti-VEGF scFv[J]. Sci Rep,2022,12(1):5449.
[10] YANG M,TANG X,ZHANG Z,et al. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors[J]. Theranostics,2020,10(17):7622-7634.
[11] FLEETWOOD F,GULER R,GORDON E,et al. Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling[J]. Cell Mol Life Sci,2016,73(8):1671-1683.
[12] DE AGUIAR R B,DA SILVA T A,COSTA B A,et al. Generation and functional characterization of a single-chain variable fragment (scFv) of the anti-FGF2 3F12E7 monoclonal antibody[J]. Sci Rep,2021,11(1):1432.
[13] LOOMANS E E,ROELEN A J,VAN DAMMe H S,et al. Assessment of the functional affinity constant of monoclonal antibodies using an improved enzyme-linked immunosorbent assay[J]. J Immunol Methods,1995,184(2):207-217.
[14] WU X,DEMAREST S J. Building blocks for bispecific and trispecific antibodies[J]. Methods,2019,154:3-9.
[15] ZHOU H X. Quantitative account of the enhanced affinity of two linked scFvs specific for different epitopes on the same antigen[J]. J Mol Biol,2003,329(1):1-8.
[16] FLEETWOOD F,KLINT S,HANZE M,et al. Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic affibody molecules results in dramatically improved affinity[J]. Sci Rep,2014,4:7518.
[17] WATANABE Y,TANABE A,HAMAKUBO T,et al. Development of biparatopic bispecific antibody possessing tetravalent scFv-Fc capable of binding to ROBO1 expressed in hepatocellular carcinoma cells[J]. J Biochem,2021,170(2): 307-315.
[18] ASANO R,KUROKI Y,HONMA S,et al. Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells[J]. MAbs,2018,10(6):854-863.
[19] KORN T,NETTELBECK D M,VOLKEL T,et al. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv[J]. J Gene Med,2004,6(6): 642-651.
[1]杨冬梅综述,庞丽红审校.胎盘生长因子在早期妊娠中的研究进展[J].天津医科大学学报,2022,28(03):339.